Gynecomastia, colloquially known as “gyno” or informally as “bitch tits,” refers to the abnormal development of breast tissue in males.
It is primarily caused by the action of estrogen, estrogen analogues, or estrogenic compounds, with high estrogen levels or hormonal imbalances being the main culprits.
Causes
Anabolic Steroid Use
Caused by aromatization (the conversion of androgens to estrogen) or by estrogenically active drugs.
Puberty
Occurs in about 50% of adolescent males due to hormonal fluctuations during puberty, and it typically resolves within two years.
Age
Estrogen dominance resulting from a decline in testosterone (andropause).
Obesity
The aromatase enzyme in adipose (fat) tissue converts androgens into estrogen.
Genetics and Sensitivity
Certain individuals are more susceptible to gynecomastia.
Pathogenesis
Estrogen stimulates the growth of breast tissue by binding to estrogen receptors within that tissue.
Androgens inhibit this growth, while Dihydrotestosterone (DHT) acts as a natural anti-estrogen.
Prevention and Management
Prevention for Anabolic Steroid Users
Preventative measures (e.g., using AIs or SERMs) are necessary depending on the aromatizing properties of the steroid and individual sensitivity.
Treatability
In some cases, it can be managed with medication, but severe cases may require surgery.
Education and Responsible Use
In today’s environment with accessible information, preventing gynecomastia is possible, and ignorance is not considered an excuse.
Gynecomastia is a treatable condition, and its occurrence can be minimized through prevention and management.
The following is an analysis of various drugs of concern related to gynecomastia.
Aromatizable Anabolic Steroids (High Rate of Aromatization)
- Cheque Drops (Mibolerone)
- Methyltestosterone
Aromatizable Anabolic Steroids (Moderate Rate of Aromatization)
- Testosterone (all esters and blends)
- Dianabol (Methandrostenolone)
Aromatizable Anabolic Steroids (Low Rate of Aromatization)
- Deca Durabolin (Nandrolone Decanoate)
- Equipoise (Boldenone Undecylenate)
- Nandrolone Phenylpropionate
Directly Estrogenic Anabolic Steroids
- Anadrol 50 (Oxymetholone)
Progestational Anabolic Steroids
- Deca Durabolin (Nandrolone Decanoate)
- Nandrolone Phenylpropionate
- Trenbolone
A higher rate of aromatization creates a state of estrogen dominance, increasing the likelihood of developing gynecomastia.
This is related to the process where the aromatase enzyme converts androgens into estrogen.
Different androgens vary in the degree to which they interact with the aromatase enzyme.
Steroids like Anadrol (Oxymetholone) do not convert to estrogen but can exhibit direct estrogenic activity in breast tissue.
Conversely, DHT-derivative steroids like Anavar (Oxandrolone) or Winstrol (Stanozolol) do not convert to estrogen and therefore do not cause gynecomastia.
Progestin-based steroids like Nandrolone or Trenbolone do not convert to estrogen but can cause gynecomastia by interacting with progesterone receptors, which increases estrogen sensitivity.
Notably, this effect can occur even with low estrogen levels.
Prolactin is not a direct cause of gynecomastia but can lead to nipple puffiness or lactation.
These conditions can be alleviated with prolactin inhibitors.
To prevent or treat gynecomastia, it is effective to lower estrogen levels and inhibit receptor activity using SERMs or AIs.
Increasing testosterone and DHT levels is also an important management strategy.
In conclusion, gynecomastia arises from the complex interaction of various hormonal factors, including estrogen, progesterone, and prolactin, and it is crucial to accurately understand and manage its causes.
Diagnosis, Prevention, and Treatment of Gynecomastia
Understanding the mechanisms and developmental processes of gynecomastia at the cellular and hormonal levels makes it easier to identify methods for treatment and prevention.
However, an accurate diagnosis must come first.
In many cases, conditions that are not actually gynecomastia are frequently mistaken for the disorder.
These misunderstandings stem from excessive worry and a lack of understanding of the symptoms.
Although gynecomastia is considered a common side effect of anabolic steroid use, it is actually one of the easiest conditions to prevent.
Diagnosis
The diagnosis of gynecomastia is very straightforward, and its distinct symptoms can be easily recognized even by a layperson.
A diagnosis is based on clear observation, not speculation.
The speed of development and severity depend on the type, dosage, and duration of anabolic steroid use, as well as individual sensitivity.
Some individuals may have no symptoms despite high estrogen levels, while others can develop the condition with only a slight increase.
Gynecomastia can appear bilaterally or unilaterally, and an increase in areola diameter and asymmetrical chest tissue development are also key signs.
Ultrasound imaging is used for diagnosis, and a tissue biopsy can be performed via fine-needle aspiration.
Gynecomastia progresses in three stages.
- Sensitivity and pain (reversible).
- Development of puffiness (before glandular tissue develops).
- Full development of glandular and fatty tissue (irreversible).
The rate of development varies depending on an individual’s hormonal environment and the causal factors, and it can progress in a matter of weeks or even days.
In some cases, it may remain at a specific stage.
The severity is graded as follows.
- Minor enlargement without excess skin.
- Moderate enlargement without excess skin.
- Moderate enlargement with excess skin.
- Marked enlargement with excess skin.
Prevention and Treatment
The prevention and treatment of gynecomastia are closely intertwined.
In particular, an understanding of the drugs and compounds used to mitigate or prevent it is essential.
Prevention requires techniques beyond the use of drugs or supplements, which will be explained next.
First, one must thoroughly understand the mechanisms of action and applications of the various tools and compounds used in the treatment and prevention of gynecomastia.
Selective Estrogen Receptor Modulators (SERMs)
SERMs (Selective Estrogen Receptor Modulators) play a crucial role in the prevention and treatment of gynecomastia.
Originally developed to treat estrogen receptor-positive breast cancer, they have proven effective in preventing, inhibiting, or halting gynecomastia because it develops through the same hormonal pathway.
However, SERMs are not FDA-approved for the treatment of gynecomastia.
At the cellular level, SERMs occupy estrogen receptors, preventing estrogen from binding to them and thereby blocking estrogen’s activity in breast tissue.
This is known as ‘estrogen antagonism.’
SERMs do not lower total estrogen levels in the body but rather block the effects of estrogen in specific tissues.
Common SERMs include Nolvadex (Tamoxifen), Clomid (Clomiphene), Fareston (Toremifene), and Evista (Raloxifene).
Aromatase Inhibitors (AIs)
AIs (Aromatase Inhibitors) work by lowering estrogen levels in the body, which can bring elevated estrogen levels that cause gynecomastia down to normal physiological levels.
Estrogen is produced when aromatizable androgens, like testosterone, are converted by the aromatase enzyme.
AIs bind to this aromatase enzyme, inhibiting its activity and consequently blocking estrogen production.
Some AIs temporarily inhibit the enzyme, while others, like Aromasin, permanently disable it.
The strength and efficacy of an AI depend on its efficiency in inhibiting the enzyme; for example, Letrozole exhibits a potent inhibitory effect.
Common AIs include Arimidex (Anastrozole), Aromasin (Exemestane), and Femara (Letrozole).
Dihydrotestosterone (DHT) Cream
Some anecdotal evidence suggests that applying a topical DHT cream to the nipples and chest area may be effective in preventing gynecomastia.
However, there is a lack of clinical data to support this, and prevention with drugs like SERMs and AIs is more widely practiced.
DHT acts as an anti-estrogen in the body, which can help prevent gynecomastia.
However, for gynecomastia that has been present for more than a year, surgical treatment may be necessary.
There are three methods for preventing gynecomastia
1. Dose Control and Moderate Dosing: This is the most economical and effective method, involving the proper adjustment of steroid dosage. For example, using a low dose of testosterone can help avoid a spike in estrogen.
2. SERM Use: This method involves using a SERM daily during an anabolic steroid cycle.
A daily dose of 20mg is used to block estrogen receptors and prevent the development of gynecomastia.
However, continuous use of SERMs can lead to a decrease in IGF-1 levels.
3. AI Use: This method involves using an AI during an anabolic steroid cycle to control estrogen levels.
This approach is commonly used in the bodybuilding community.
